Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients

Sponsor

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (Other)

Overall Status

Completed

CT.gov ID

NCT04880460

Collaborator

(none)

Enrollment

Location

Arms

8.1

Actual Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A randomized, double-blind, placebo-controlled trial was conducted to assess the effect of magnesium glycinate on symptoms of moderate to severe depression in 90 patients. Patients were assessed at baseline, end of the 4 weeks, and end of the 8 weeks of treatment. Patients were randomized to receive either 200 mg elemental magnesium or 200 mg placebo tablet twice daily for 8 weeks. The primary outcome measure was depression severity score assessment using Depression Anxiety Stress Scale 21 items Bangla Version (DASS-21 BV) and the secondary outcome measure was serum magnesium level estimation and side effects assessment using a preformed checklist.

Condition or Disease	Intervention/Treatment	Phase
MDD	Dietary Supplement: Magnesium Glycinate tablet 200mg Dietary Supplement: Placebo tablet 200mg	Phase 2

Detailed Description

Major depressive disorder (MDD), is a mood disorder affecting 300 million people worldwide with a prevalence of 6.7% in Bangladesh. Depression is the main contributor to suicidal deaths and is globally ranked as the single largest contributor to non-fatal health loss. Various psychological, genetic, environmental, and biochemical factors are presumed to be involved in the causation of MDD. About 30% to 50% of patients do not respond to initial antidepressant medication, and 15% of them continue to suffer from symptoms despite the completion of multiple antidepressants and more aggressive treatment regimens, in addition to facing untoward adverse drug reactions with increasing dose. Recent trials attempted to assess the effect of magnesium in reducing depressive symptoms in MDD patients. This study evaluates whether there was any role of magnesium in reducing depressive symptoms between those who did and did not receive magnesium in 8 weeks period. Patients attending the Outpatient Department of Psychiatry, BSMMU, and diagnosed with MDD were evaluated using the DASS-21 BV for assessment of severity. Those patients who were experiencing moderate to severe symptoms (scores of 14-27) were enrolled according to inclusion and exclusion criteria. Total enrolled 90 MDD patients who have received either 200 mg elemental magnesium twice daily in the form of magnesium glycinate tablet or 200 mg placebo tablet twice daily for 8 weeks. A baseline depression severity score assessment was done using DASS-21 items and again repeated at the end of the 4 weeks and 8 weeks of treatment. Initially, baseline serum magnesium level (mg/dL) was measured and repeated again at the end of the 8 weeks of treatment. DASS-21 is a validated set of three self-report scales to measure the state of depression, anxiety, and stress, where each of the three scales contains 7 items, and each item is rated from 0 to 3. The depression scale assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest, anhedonia, and inertia.

Study Design

Study Type:

Interventional

Actual Enrollment :

90 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

A type of intervention model describing a clinical trial in which two or more groups of participants receive different interventions. For example, a two-arm parallel assignment involves two groups of participants. One group receives drug A, and the other group receives drug B. So during the trial, participants in one group receive drug A "in parallel" to participants in the other group, who receive drug B.A type of intervention model describing a clinical trial in which two or more groups of participants receive different interventions. For example, a two-arm parallel assignment involves two groups of participants. One group receives drug A, and the other group receives drug B. So during the trial, participants in one group receive drug A "in parallel" to participants in the other group, who receive drug B.

Masking:

Double (Participant, Investigator)

Masking Description:

A clinical trial design strategy in which one or more parties involved in the trial, such as the investigator or participants, do not know which participants have been assigned which interventions. The type of masking was double-blind masking.

Primary Purpose:

Treatment

Official Title:

Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

Actual Study Start Date :

Mar 18, 2021

Actual Primary Completion Date :

Nov 21, 2021

Actual Study Completion Date :

Nov 21, 2021

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Experimental 45 MDD patients were included in this arm who were received SSRIs and Magnesium tablets	Dietary Supplement: Magnesium Glycinate tablet 200mg Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs
Placebo Comparator: Control 45 MDD patients were included in this arm who were received SSRIs and placebo tablets	Dietary Supplement: Placebo tablet 200mg Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs

Arm

Intervention/Treatment

Active Comparator: Experimental

45 MDD patients were included in this arm who were received SSRIs and Magnesium tablets

Dietary Supplement: Magnesium Glycinate tablet 200mg

Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs

Placebo Comparator: Control

45 MDD patients were included in this arm who were received SSRIs and placebo tablets

Dietary Supplement: Placebo tablet 200mg

Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs

Outcome Measures

Primary Outcome Measures

Depression severity score assessment [8 weeks]
Assessed the severity score of depressive symptoms using DASS-21 at baseline, end of the 4 weeks, and end of the 8 weeks treatment. Compared the score between before and after treatment. Compared the score between two arms. DASS21 score range from 0-28+ with the following scores: 0-9 Normal, 10-13 Mild, 14-20 Moderate, 21-27 Severe, 28+ Extremely severe.

Secondary Outcome Measures

Biochemical assessment [8 weeks]
Serum magnesium level (mg/dL) was measured at baseline and end of the 8 weeks treatment. Compared the serum magnesium level (mg/dL) between before and after treatment. Compare the serum magnesium level (mg/dL) between two arms.
Side effects assessment [8 weeks]
Participants were asked about the side effects using a preformed checklist. And compare the effects between two arms.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Newly diagnosed 18 years or older MDD patients of both gender according to DSM-5 at the Outpatient Department of Psychiatry, BSMMU
Moderate to severe MDD according to DASS-21 (scores of 14-27)
Patients prescribed only SSRIs

Exclusion Criteria:

Patients having any other psychiatric disease, kidney disease, or gastrointestinal disease
Taking dietary supplements in the last two months
Taking fluoroquinolones, aminoglycosides, tetracyclines, calcium channel blockers, bisphosphonates, and skeletal muscle relaxants
Pregnancy and lactation

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Basic Science and Paraclinical Science of BSMMU	Dhaka		Bangladesh

Sponsors and Collaborators

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Investigators

Study Chair: Prof. Md. Sayedur Rahman, MBBS, MPhil, FCPS, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Dr. Sarmin Sultana, Principal Investigator, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

ClinicalTrials.gov Identifier:

NCT04880460

Other Study ID Numbers:

BSMMU/2021/257

First Posted:

May 10, 2021

Last Update Posted:

Mar 21, 2022

Last Verified:

Nov 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Product Manufactured in and Exported from the U.S.:

Keywords provided by Dr. Sarmin Sultana, Principal Investigator, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

MDD

Magnesium

DASS-21

Serum magnesium level

Additional relevant MeSH terms:

Depressive Disorder

Depressive Disorder, Major

Study Results

No Results Posted as of Mar 21, 2022